USA - NASDAQ:EKSO - US2826444000 - Common Stock
The current stock price of EKSO is 4.85 USD. In the past month the price decreased by -9.18%. In the past year, price decreased by -62.4%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.04 | 217.47B | ||
| ISRG | INTUITIVE SURGICAL INC | 63.62 | 196.37B | ||
| BSX | BOSTON SCIENTIFIC CORP | 33.58 | 146.77B | ||
| SYK | STRYKER CORP | 26.86 | 135.27B | ||
| IDXX | IDEXX LABORATORIES INC | 56.6 | 57.10B | ||
| BDX | BECTON DICKINSON AND CO | 12.3 | 50.85B | ||
| EW | EDWARDS LIFESCIENCES CORP | 32.08 | 48.40B | ||
| RMD | RESMED INC | 25.22 | 36.43B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 16.16 | 33.86B | ||
| PODD | INSULET CORP | 76.45 | 22.76B | ||
| DXCM | DEXCOM INC | 31.19 | 22.75B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 10.94 | 17.53B |
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
EKSO BIONICS HOLDINGS INC
101 Glacier Point, Suite A
San Rafael California CALIFORNIA 94804 US
CEO: Jack Peurach
Employees: 64
Phone: 15109841761
Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company is headquartered in San Rafael California, California and currently employs 61 full-time employees. The company went IPO on 2013-04-10. Its exoskeleton technology serves people with physical disabilities or impairments in both physical rehabilitation and mobility. The company operates as one segment with two markets: Enterprise Health and Personal Health. Its products include EksoNR, which is a wearable robotic exoskeleton designed for a rehabilitation setting; Ekso Indego Therapy is a modular, adjustable, lightweight, lower limb-powered exoskeleton; Ekso Indego Personal is a lower limb orthosis; Ekso Nomad is a power Knee Ankle Foot Orthosis, and Ekso EVO is a wearable upper body exoskeleton. The company enables individuals with neurological conditions affecting gait, including acquired brain injury (ABI) and spinal cord injury (SCI), to rehabilitate, stand and walk again. Additionally, the devices assist people with a variety of upper extremity disabilities and enable industrial employees to perform challenging repetitive tasks for extended periods.
The current stock price of EKSO is 4.85 USD. The price decreased by -7.62% in the last trading session.
EKSO does not pay a dividend.
EKSO has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
EKSO BIONICS HOLDINGS INC (EKSO) operates in the Health Care sector and the Health Care Equipment & Supplies industry.
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on EKSO.
The outstanding short interest for EKSO BIONICS HOLDINGS INC (EKSO) is 4.18% of its float.
ChartMill assigns a technical rating of 5 / 10 to EKSO. When comparing the yearly performance of all stocks, EKSO turns out to be only a medium performer in the overall market: it outperformed 43.13% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to EKSO. EKSO has a bad profitability rating. Also its financial health evaluation is rather negative.
Over the last trailing twelve months EKSO reported a non-GAAP Earnings per Share(EPS) of -5.68. The EPS increased by 41.74% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -49.21% | ||
| ROE | -110.14% | ||
| Debt/Equity | 0.31 |
8 analysts have analysed EKSO and the average price target is 35.45 USD. This implies a price increase of 630.82% is expected in the next year compared to the current price of 4.85.
For the next year, analysts expect an EPS growth of 47.03% and a revenue growth -7.06% for EKSO